Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 185

1.

Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy.

Yukl SA, Gianella S, Sinclair E, Epling L, Li Q, Duan L, Choi AL, Girling V, Ho T, Li P, Fujimoto K, Lampiris H, Hare CB, Pandori M, Haase AT, Günthard HF, Fischer M, Shergill AK, McQuaid K, Havlir DV, Wong JK.

J Infect Dis. 2010 Nov 15;202(10):1553-61. doi: 10.1086/656722. Epub 2010 Oct 12.

2.

Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy.

Yukl SA, Shergill AK, McQuaid K, Gianella S, Lampiris H, Hare CB, Pandori M, Sinclair E, Günthard HF, Fischer M, Wong JK, Havlir DV.

AIDS. 2010 Oct 23;24(16):2451-60. doi: 10.1097/QAD.0b013e32833ef7bb.

3.

Cellular HIV-1 DNA levels in patients receiving antiretroviral therapy strongly correlate with therapy initiation timing but not with therapy duration.

Watanabe D, Ibe S, Uehira T, Minami R, Sasakawa A, Yajima K, Yonemoto H, Bando H, Ogawa Y, Taniguchi T, Kasai D, Nishida Y, Yamamoto M, Kaneda T, Shirasaka T.

BMC Infect Dis. 2011 May 24;11:146. doi: 10.1186/1471-2334-11-146.

4.

Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.

Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, Macken CA, Perelson AS, Wolinsky SM.

N Engl J Med. 1999 May 27;340(21):1614-22.

5.

The distribution of HIV DNA and RNA in cell subsets differs in gut and blood of HIV-positive patients on ART: implications for viral persistence.

Yukl SA, Shergill AK, Ho T, Killian M, Girling V, Epling L, Li P, Wong LK, Crouch P, Deeks SG, Havlir DV, McQuaid K, Sinclair E, Wong JK.

J Infect Dis. 2013 Oct 15;208(8):1212-20. doi: 10.1093/infdis/jit308. Epub 2013 Jul 12.

6.

Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection.

Ananworanich J, Schuetz A, Vandergeeten C, Sereti I, de Souza M, Rerknimitr R, Dewar R, Marovich M, van Griensven F, Sekaly R, Pinyakorn S, Phanuphak N, Trichavaroj R, Rutvisuttinunt W, Chomchey N, Paris R, Peel S, Valcour V, Maldarelli F, Chomont N, Michael N, Phanuphak P, Kim JH; RV254/SEARCH 010 Study Group.

PLoS One. 2012;7(3):e33948. doi: 10.1371/journal.pone.0033948. Epub 2012 Mar 30.

7.

Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy.

Kaufmann GR, Bloch M, Zaunders JJ, Smith D, Cooper DA.

AIDS. 2000 May 26;14(8):959-69.

PMID:
10853977
8.

T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy.

Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, Deeks SG.

J Infect Dis. 2003 May 15;187(10):1534-43. Epub 2003 Apr 23.

9.

Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.

Hoen B, Cooper DA, Lampe FC, Perrin L, Clumeck N, Phillips AN, Goh LE, Lindback S, Sereni D, Gazzard B, Montaner J, Stellbrink HJ, Lazzarin A, Ponscarme D, Staszewski S, Mathiesen L, Smith D, Finlayson R, Weber R, Wegmann L, Janossy G, Kinloch-de Loes S; QUEST Study Group.

Clin Infect Dis. 2007 Aug 1;45(3):381-90. Epub 2007 Jun 26.

10.

Lack of correlation between the size of HIV proviral DNA reservoir and the level of immune activation in HIV-infected patients with a sustained undetectable HIV viral load for 10 years.

Poizot-Martin I, Faucher O, Obry-Roguet V, Nicolino-Brunet C, Ronot-Bregigeon S, Dignat-George F, Tamalet C.

J Clin Virol. 2013 Aug;57(4):351-5. doi: 10.1016/j.jcv.2013.04.007. Epub 2013 May 8.

PMID:
23664725
11.

Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial.

Chege D, Kovacs C, la Porte C, Ostrowski M, Raboud J, Su D, Kandel G, Brunetta J, Kim CJ, Sheth PM, Kaul R, Loutfy MR.

AIDS. 2012 Jan 14;26(2):167-74. doi: 10.1097/QAD.0b013e32834e8955.

PMID:
22089379
12.
13.

The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.

Schapiro JM, Winters MA, Stewart F, Efron B, Norris J, Kozal MJ, Merigan TC.

Ann Intern Med. 1996 Jun 15;124(12):1039-50.

PMID:
8633817
14.

Early initiation of highly active antiretroviral therapy fails to reverse immunovirological abnormalities in gut-associated lymphoid tissue induced by acute HIV infection.

Tincati C, Biasin M, Bandera A, Violin M, Marchetti G, Piacentini L, Vago GL, Balotta C, Moroni M, Franzetti F, Clerici M, Gori A.

Antivir Ther. 2009;14(3):321-30.

PMID:
19474466
15.

Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.

Llibre JM, Buzón MJ, Massanella M, Esteve A, Dahl V, Puertas MC, Domingo P, Gatell JM, Larrouse M, Gutierrez M, Palmer S, Stevenson M, Blanco J, Martinez-Picado J, Clotet B.

Antivir Ther. 2012;17(2):355-64. doi: 10.3851/IMP1917. Epub 2011 Sep 28.

PMID:
22290239
16.

A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy.

Deeks SG, Wagner B, Anton PA, Mitsuyasu RT, Scadden DT, Huang C, Macken C, Richman DD, Christopherson C, June CH, Lazar R, Broad DF, Jalali S, Hege KM.

Mol Ther. 2002 Jun;5(6):788-97.

17.

Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication.

Alatrakchi N, Duvivier C, Costagliola D, Samri A, Marcelin AG, Kamkamidze G, Astriti M, Agher R, Calvez V, Autran B, Katlama C.

AIDS. 2005 Jan 3;19(1):25-33.

PMID:
15627030
18.

Epstein-Barr virus load and immune activation in human immunodeficiency virus type 1-infected patients.

Petrara MR, Cattelan AM, Zanchetta M, Sasset L, Freguja R, Gianesin K, Cecchetto MG, Carmona F, De Rossi A.

J Clin Virol. 2012 Mar;53(3):195-200. doi: 10.1016/j.jcv.2011.12.013. Epub 2011 Dec 30.

PMID:
22209290
19.

Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies.

Tebas P, Henry K, Mondy K, Deeks S, Valdez H, Cohen C, Powderly WG.

J Infect Dis. 2002 Sep 15;186(6):851-4. Epub 2002 Aug 28. Erratum in: J Infect Dis 2002 Oct 15;186(8):1198.

20.

Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.

Imaz A, Olmo M, Peñaranda M, Gutiérrez F, Romeu J, Larrousse M, Domingo P, Oteo JA, Curto J, Vilallonga C, Masiá M, López-Aldeguer J, Iribarren JA, Podzamczer D; STOPAR study team.

Antivir Ther. 2013;18(1):125-30. doi: 10.3851/IMP2249. Epub 2012 Jul 18.

PMID:
22805174
Items per page

Supplemental Content

Write to the Help Desk